Pioglitazone - Article Actos
Article: Pioglitazone
![]() | |
Pioglitazone | |
Systematic (IUPAC) name | |
5-((4-(2-(5-ethyl-2-pyridinyl) ethoxy)phenyl)methyl)-,(+-)- 2,4-thiazolidinedione, | |
Identifiers | |
CAS number | 111025-46-8 |
ATC code | A10BG03 |
PubChem | 4829 |
DrugBank | APRD00653 |
Chemical data | |
Formula | C19H20N2O3S |
Mol. weight | 356.44 g/mol |
Pharmacokinetic data | |
Bioavailability | ? |
Protein binding | > 99% |
Metabolism | ? |
Half life | 3-7 hours |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. | ? |
Legal status | |
Routes | ? |
In medicine and pharmacology, pioglitazone is a member of the drug class of the thiazolidinediones.
It is being marketed as Actos® by the pharmaceutical companies Takeda and Eli Lilly.
Like other thiazolidinediones, its mechanism of action is by activation the intracellular receptor class of the peroxisome proliferator-activated receptors (PPARs), specifically PPARγ.
Side-effects and contraindications
- See main article: thiazolidinedione
See also
- Anti-diabetic drugs
- Peroxisome proliferator-activated receptor
Resources
- Actos (Drug Digest)
- Actos Consumer Information (U.S. Food and Drug Administration)